8-K: Sharps Technology Secures $236.6M At-The-Market Equity Offering

Sharps Technology, Inc. has entered into an At-The-Market (ATM) equity offering sales agreement to potentially raise up to $236.6 million through the sale of common stock.

Summary

• Sharps Technology, Inc. (the "Company") entered into a Controlled Equity Offering Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. and Aegis Capital Corp. (the "Agents") on September 2, 2025.
• The Sales Agreement allows the Company to offer and sell shares of its common stock, par value $0.0001 per share, with an aggregate sales price of up to $236,605,575 (the "ATM Offering").
• Sales of common stock under the agreement will be made from time to time, at the Company's option, through the Agents, acting as principal and/or sole designated sales agent.
• The Agents will use commercially reasonable efforts to sell the shares based on the Company's instructions.
• The Company will pay the Agents a commission of 3.0% of the gross proceeds from each sale of shares.
• The Company has no obligation to sell any shares and may suspend offers or terminate the Sales Agreement at any time.
• The shares will be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-274146), which became effective on September 5, 2023, and a Rule 462(b) registration statement (File No. 333-289980).

Sentiment

Score: 7

Explanation: The agreement provides significant financial flexibility and access to capital, which is generally positive for a company. However, the potential for dilution introduces a degree of caution, leading to a moderately positive sentiment.

Positives

• Provides Sharps Technology with a flexible and efficient mechanism to raise capital opportunistically based on market conditions and its funding needs.
• The 'at-the-market' nature allows the Company to control the timing and volume of share sales, potentially minimizing immediate market impact compared to a single large offering.
• There is no obligation for the Company to sell any shares, offering discretion over capital deployment and dilution management.

Negatives

• Potential for significant dilution of existing shareholders if a substantial number of shares are sold under the ATM program.
• A 3.0% commission on gross proceeds will reduce the net capital raised by the Company.
• The actual amount of capital raised is uncertain and dependent on market demand and the Company's decision to sell shares.

Risks

• Market price volatility of the Company's common stock could impact the average price at which shares are sold, affecting the total proceeds raised.
• Inability to sell the full authorized amount of shares if market conditions are unfavorable or investor demand is insufficient.
• Dilution of existing shareholders' ownership percentage and earnings per share if a significant number of new shares are issued.
• The offering could create downward pressure on the stock price as new shares are introduced to the market.

Future Outlook

The agreement provides a flexible mechanism for Sharps Technology to raise capital from time to time, at its option, by selling common stock into the market. This allows the company to access funding opportunistically based on market conditions and its capital needs, supporting general corporate purposes, working capital, or strategic initiatives.

Management Comments

• The filing was signed by Paul K. Danner, Executive Chairman (Principal Executive Officer), indicating the formal execution of the Sales Agreement.

Industry Context

At-the-market (ATM) offerings are a common and flexible financing tool used by publicly traded companies to raise capital over time, minimizing the immediate market impact of a large, single offering. This allows companies to tap into public markets as needed, often for general corporate purposes or to fund ongoing operations, particularly in industries requiring continuous investment like medical technology.

Comparison to Industry Standards

• ATM offerings are a standard capital-raising mechanism, particularly for smaller-cap companies or those seeking continuous access to capital without the disruption of traditional underwritten offerings.
• The 3.0% commission rate is within the typical range for ATM offerings, which can vary from 1% to 5% depending on the company's size, liquidity, and market conditions.
• Many companies, such as small-to-mid cap biotech firms or technology companies, utilize ATMs to fund R&D, clinical trials, or operational expansion, similar to how Sharps Technology might use these proceeds.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings if the company sells a significant number of shares under the ATM program, which could impact per-share metrics.
• Company: Enhanced financial flexibility and access to capital for general corporate purposes, working capital, or strategic initiatives, potentially strengthening its balance sheet.

Next Steps

• The Company may, at its option, offer and sell shares of common stock through the Agents from time to time.
• The Agents will use commercially reasonable efforts to sell shares based on the Company's instructions.
• The Company will disclose the number of shares sold and net proceeds in future Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

Key Dates

Recommendation

The ATM offering provides Sharps Technology with a flexible mechanism to raise capital, which is a positive for long-term operational stability and strategic initiatives. However, the potential for significant share dilution, depending on the volume and price of shares sold, could exert downward pressure on the stock. Investors should monitor the company's actual utilization of the ATM and its impact on the share count and per-share metrics. Until there is clearer guidance on the use of proceeds and the extent of dilution, a 'hold' recommendation is prudent, advising investors to observe the execution of this financing strategy.

Keywords

Sharps Technology, STSS, ATM Offering, Equity Offering, Capital Raise, Common Stock, NASDAQ, Cantor Fitzgerald, Aegis Capital, SEC Filing, Form 8-K